Effect of AMP-activated protein kinase activation on cardiac fibroblast proliferation induced by coxsackievirus B3

Jiang,Shengyang; Tian,Shunli; Wu,Xueming; Tao,Yijia; Jiang,Donglin

doi:10.3892/etm.2016.3174

Effect of AMP-activated protein kinase activation on cardiac fibroblast proliferation induced by coxsackievirus B3

Authors:
- Shengyang Jiang
- Shunli Tian
- Xueming Wu
- Yijia Tao
- Donglin Jiang
View Affiliations

Affiliations: Department of Cardiology, The Third Affiliated Hospital of Nantong University, Wuxi Institute of Integrated Traditional Chinese and Western Medicine, Wuxi, Jiangsu 214041, P.R. China, Department of Geratology, Tianjin Geriatric Institute, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China, Clinical Central Laboratory, The Third Affiliated Hospital of Nantong University, Wuxi Institute of Integrated Traditional Chinese and Western Medicine, Wuxi, Jiangsu 214041, P.R. China
Published online on: March 18, 2016 https://doi.org/10.3892/etm.2016.3174
Pages: 2547-2552

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Excessive fibroblast proliferation and collagen production are the major pathogenic mechanisms in the progression of viral myocarditis, which is most frequently associated with infection by coxsackievirus B3 (CVB3). AMP-activated protein kinase (AMPK) has been confirmed to be involved in the progression of myocardial remodeling. However, it remains unclear whether AMPK has an effect on CVB3‑induced cardiac fibroblast proliferation. In the present study, the effects of AMPK on cardiac fibroblast proliferation and collagen secretion induced by CVB3 were investigated. Proliferation of neonatal cardiac fibroblasts was determined by cell counting and detection of newly synthesized DNA in cells, and the proportion of cells in the S phase was measured. Hydroxyproline ELISA was used to detect collagen secretion. Phosphorylation of AMPKα-Thr172 was evaluated by western blotting. It was found that neonatal cardiac fibroblasts were clearly proliferating markedly and secreting collagen at 24 h after CVB3 infection, and peaked at 48 h. These effects were inhibited following pretreatment of the fibroblasts with 5-aminoimidazole-4-carboxamide-ribonucleoside (AICAR), a specific AMPK activator, for 2 h prior to CVB3 infection. However, if the cells were preincubated with compound C for 30 min, the inhibitive effects of AICAR were reversed. Western blotting results indicated that AMPK α‑Thr172 phosphorylation was increased by AICAR and attenuated by Compound C. The results of the present study suggest that CVB3 infection increases cardiac fibroblast proliferation and collagen secretion, and that these phenomena can be inhibited by activated AMPK. These findings contribute to our understanding of AMPK function and the future design of therapeutic approaches for the treatment of cardiac fibrosis caused by chronic viral infection, such as CVB3-induced myocarditis.

View Figures

View References

1	Massilamany C, Huber SA, Cunningham MW and Reddy J: Relevance of molecular mimicry in the mediation of infectious myocarditis. J Cardiovasc Transl Res. 7:165–171. 2014. View Article : Google Scholar : PubMed/NCBI
2	Antoniak S and Mackman N: Coagulation, protease-activated receptors, and viral myocarditis. J Cardiovasc Transl Res. 7:203–211. 2014. View Article : Google Scholar : PubMed/NCBI
3	Cao Y, Xu W and Xiong S: Adoptive transfer of regulatory T cells protects against Coxsackievirus B3-induced cardiac fibrosis. PLoS One. 8:e749552013. View Article : Google Scholar : PubMed/NCBI
4	Shen Y, Xu W, Chu YW, Wang Y, Liu QS and Xiong SD: Coxsackievirus group B type 3 infection upregulates expression of monocyte chemoattractant protein 1 in cardiac myocytes, which leads to enhanced migration of mononuclear cells in viral myocarditis. J Virol. 78:12548–12556. 2004. View Article : Google Scholar : PubMed/NCBI
5	Lindner D, Li J, Savvatis K, Klingel K, Blankenberg S, Tschöpe C and Westermann D: Cardiac fibroblasts aggravate viral myocarditis: Cell specific coxsackievirus B3 replication. Mediators Inflamm. 2014:5195282014. View Article : Google Scholar : PubMed/NCBI
6	Brown RD, Ambler SK, Mitchell MD and Long CS: The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol. 45:657–687. 2005. View Article : Google Scholar : PubMed/NCBI
7	Hardie DG: AMPK: Positive and negative regulation and its role in whole-body energy homeostasis. Curr Opin Cell Biol. 33:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
8	Stuck BJ, Lenski M, Böhm M and Laufs U: Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J Biol Chem. 283:32562–32569. 2008. View Article : Google Scholar : PubMed/NCBI
9	Zhang CX, Pan SN, Meng RS, Peng CQ, Xiong ZJ, Chen BL, Chen GQ, Yao FJ, Chen YL, Ma YD and Dong YG: Metformin attenuates ventricular hypertrophy by activating the AMP-activated protein kinase-endothelial nitric oxide synthase pathway in rats. Clin Exp Pharmacol Physiol. 38:55–62. 2011. View Article : Google Scholar : PubMed/NCBI
10	Xie W, Wang L, Dai Q, Yu H, He X, Xiong J, Sheng H, Zhang D, Xin R, Qi Y, et al: Activation of AMPK restricts coxsackievirus B3 replication by inhibiting lipid accumulation. J Mol Cell Cardiol. 85:155–167. 2015. View Article : Google Scholar : PubMed/NCBI
11	Reed LJ and Muench H: A simple method of estimating fifty percent endpoints. Am J Hyg. 27:493–497. 1938.
12	Liu MY, Wu DL, Liu NH, Meng QW and Meng FC: 1A and 3D gene sequences of coxsackievirus B3 strain CC: Variation and phylogenetic analysis. DNA Seq. 19:8–12. 2008. View Article : Google Scholar : PubMed/NCBI
13	Leipner C, Grün K, Schneider I, Glück B, Sigusch HH and Stelzner A: Coxsackievirus B3-induced myocarditis: Differences in the immune response of C57BL/6 and Balb/c mice. Med Microbiol Immunol. 193:141–147. 2004. View Article : Google Scholar : PubMed/NCBI
14	Chapman NM and Kim KS: Persistent coxsackievirus infection: Enterovirus persistence in chronic myocarditis and dilated cardiomyopathy. Curr Top Microbiol Immunol. 323:275–292. 2008.PubMed/NCBI
15	Pankuweit S and Klingel K: Viral myocarditis: From experimental models to molecular diagnosis in patients. Heart Fail Rev. 18:683–702. 2013. View Article : Google Scholar : PubMed/NCBI
16	Bhattacharjee A and Bansal M: Collagen structure: The Madras triple helix and the current scenario. IUBMB Life. 57:161–172. 2005. View Article : Google Scholar : PubMed/NCBI
17	Kasyanov V, Moreno-Rodriguez RA, Kalejs M, Ozolanta I, Stradins P, Wen X, Yao H and Mironov V: Age-related analysis of structural, biochemical and mechanical properties of the porcine mitral heart valve leaflets. Connect Tissue Res. 54:394–402. 2013. View Article : Google Scholar : PubMed/NCBI
18	Liu WY and Jiang RS: Advances in the research of AMPK and its subunit genes. Pak J Biol Sci. 16:1459–1468. 2013. View Article : Google Scholar : PubMed/NCBI
19	Xiao B, Sanders MJ, Underwood E, Heath R, Mayer FV, Carmena D, Jing C, Walker PA, Eccleston JF, Haire LF, et al: Structure of mammalian AMPK and its regulation by ADP. Nature. 472:230–233. 2011. View Article : Google Scholar : PubMed/NCBI
20	Baron SJ, Li J, Russell RR III, Neumann D, Miller EJ, Tuerk R, Wallimann T, Hurley RL, Witters LA and Young LH: Dual mechanisms regulating AMPK kinase action in the ischemic heart. Circ Res. 96:337–345. 2005. View Article : Google Scholar : PubMed/NCBI
21	Ma Y, Wang J, Gao J, Yang H, Wang Y, Manithody C, Li J and Rezaie AR: Antithrombin up-regulates AMP-activated protein kinase signalling during myocardial ischaemia/reperfusion injury. Thromb Haemost. 113:338–349. 2015. View Article : Google Scholar : PubMed/NCBI
22	Li Y, Chen C, Yao F, Su Q, Liu D, Xue R, Dai G, Fang R, Zeng J, Chen Y, et al: AMPK inhibits cardiac hypertrophy by promoting autophagy via mTORC1. Arch Biochem Biophys. 558:79–86. 2014. View Article : Google Scholar : PubMed/NCBI
23	Beauloye C, Bertrand L, Horman S and Hue L: AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc Res. 90:224–233. 2011. View Article : Google Scholar : PubMed/NCBI
24	Kim AS, Miller EJ, Wright TM, Li J, Qi D, Atsina K, Zaha V, Sakamoto K and Young LH: A small molecule AMPK activator protects the heart against ischemia-reperfusion injury. J Mol Cell Cardiol. 51:24–32. 2011. View Article : Google Scholar : PubMed/NCBI
25	Paiva MA, Rutter-Locher Z, Gonçalves LM, Providência LA, Davidson SM, Yellon DM and Mocanu MM: Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. Am J Physiol Heart Circ Physiol. 300:H2123–H2134. 2011. View Article : Google Scholar : PubMed/NCBI
26	Li HL, Yin R, Chen D, Liu D, Wang D, Yang Q and Dong YG: Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy. J Cell Biochem. 100:1086–1099. 2007. View Article : Google Scholar : PubMed/NCBI
27	Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, Anaya-Cisneros M, Tian R and Lefer DJ: Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 104:403–411. 2009. View Article : Google Scholar : PubMed/NCBI
28	Yamazaki KG, Gonzalez E and Zambon AC: Crosstalk between the renin-angiotensin system and the advance glycation end product axis in the heart: Role of the cardiac fibroblast. J Cardiovasc Transl Res. 5:805–813. 2012. View Article : Google Scholar : PubMed/NCBI